Earnings summaries and quarterly performance for AtriCure.
Executive leadership at AtriCure.
Michael H. Carrel
Detailed
President and Chief Executive Officer
CEO
Angela L. Wirick
Detailed
Chief Financial Officer
Douglas J. Seith
Detailed
Chief Operating Officer
Justin J. Noznesky
Detailed
Chief Marketing and Strategy Officer
Karl S. Dahlquist
Detailed
Chief Legal Officer
Salvatore Privitera
Detailed
Chief Technical Officer
Vinayak Doraiswamy
Detailed
Chief Scientific Officer
Board of directors at AtriCure.
Research analysts who have asked questions during AtriCure earnings calls.
Marie Thibault
BTIG
4 questions for ATRC
Also covers: ABT, ARAY, BSX +14 more
Suraj Kalia
Oppenheimer & Co. Inc.
4 questions for ATRC
Also covers: ABT, AORT, BFLY +14 more
Danielle Antalffy
UBS Group AG
3 questions for ATRC
Also covers: ABT, BAX, BSX +15 more
Daniel Stauder
Citizen JMP
3 questions for ATRC
Also covers: AORT, AVNS, LMAT +2 more
Lilia-Celine Lozada
JPMorgan Chase & Co.
3 questions for ATRC
Also covers: BVS, CBLL, IART +4 more
Matthew O'Brien
Piper Sandler & Co.
3 questions for ATRC
Also covers: APYX, ATEC, BBNX +18 more
Michael Matson
Needham & Company
3 questions for ATRC
Also covers: AORT, CNMD, ENOV +22 more
William Plovanic
Canaccord Genuity
3 questions for ATRC
Also covers: CBLL, CVRX, DXCM +9 more
John McAulay
Stifel
2 questions for ATRC
Also covers: AORT, PROF
Danielle Antalffy
UBS
1 question for ATRC
Also covers: BSX, DXCM, JNJ
Frederick Wise
Stifel
1 question for ATRC
Also covers: AORT, AVNS, BDX +13 more
Joseph Conway
Needham & Company, LLC
1 question for ATRC
Also covers: AORT, ENOV, HOLX +6 more
Lilly Quezada
JPMorgan Chase & Co.
1 question for ATRC
Zachary Day
Canaccord Genuity
1 question for ATRC
Also covers: TMDX
Recent press releases and 8-K filings for ATRC.
AtriCure Discusses Product Growth and Financial Outlook
ATRC
Product Launch
Revenue Acceleration/Inflection
Guidance Update
- AtriCure's Flex Mini clip, launched in Q4 last year, significantly drove Q3 growth by 18.5% and has achieved over 30% system penetration, offering a price increase from $1,750 (Flex-V) to $2,250.
- The Encompass clamp accounts for over 50% of U.S. revenue , and the Box No AF trial, with approximately 1,000 patients, aims to reduce post-operative AFib from 35-40% to under 10%, with initial data anticipated around early 2028.
- The pain management business, boosted by cryoSPHERE MAX, is targeting substantial markets including 150,000 thoracic and 250,000 sternotomy procedures, and 90,000 lower limb amputations for the $3,500 XT device.
- The company is focused on achieving 100 basis points of annual EBITDA margin expansion and mid-teens revenue growth, aiming for $1 billion in revenue by the end of the decade, with potential for net income in Q4.
3 days ago
AtriCure Highlights Product Innovation and Market Expansion with Strong Financial Performance
ATRC
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- AtriCure's clip business experienced 18.5% growth in Q3, an acceleration over the prior six quarters, driven by the Flex Mini product, which is 60% smaller and has achieved 30% penetration in systems in months. The Flex Mini carries an average selling price (ASP) of $2,250, an increase from the Flex-V's $1,750.
- The Encompass clamp now contributes over 50% of US revenue and has significantly reduced procedure times from 30-40 minutes to under 10 minutes.
- The company's Box No AF trial, involving approximately 1,000 patients, aims to reduce post-operative AFib from 35-40% to below 10%. Enrollment is currently exceeding internal goals, with initial data potentially leading to an advanced label.
- The pain management business is performing well, fueled by cryoSPHERE MAX and the new XT device for amputation pain, which targets a US market of 180,000-190,000 amputations at an ASP of approximately $3,500.
- AtriCure achieved a $25 million EBITDA improvement this year, surpassing its annual goal of 100 basis points of EBITDA margin expansion, and anticipates potential net income in Q4. The company projects mid-teens revenue growth with a long-term target of $1 billion by the end of the decade.
3 days ago
AtriCure Highlights Strong Product Growth and Financial Outlook
ATRC
Product Launch
Guidance Update
New Projects/Investments
- AtriCure's Flex Mini clip drove an 18.5% acceleration in Q3 clip business, achieving 30% system penetration and an average selling price of $2,250. The Encompass clamp now accounts for over 50% of U.S. revenue, significantly reducing procedure times.
- The company is progressing with the Box No AF trial, with data expected in early 2028, and is developing a combined RF and PFA device for faster ablation times, with first-in-human trials by year-end.
- AtriCure's pain management business is expanding with cryoSPHERE MAX and the new XT device for amputations, targeting large markets including 150,000 thoracic and 250,000 sternotomy procedures annually.
- Financially, AtriCure projects $25 million in EBITDA improvement this year, anticipates net income in Q4, and targets mid-teens revenue growth to reach $1 billion by the end of the decade.
3 days ago
AtriCure Discusses Product Pipeline, Clinical Trials, and Financial Outlook at Stifel 2025 Healthcare Conference
ATRC
Product Launch
New Projects/Investments
Guidance Update
- AtriCure is expanding its product portfolio with the recent launch of the XT product for extremities, expected to contribute significantly to revenue in 2026 and 2027, and the CryoSphere MAX for sternotomy patients. An open-ended AtriClip product is also planned for early 2027.
- The company is conducting significant clinical trials, including the Box No AF trial for post-operative atrial fibrillation, with initial data expected by 2028, which could potentially double the addressable patient population. The LEAPS trial for non-AFib patients is also progressing, with data potentially available before 2030.
- AtriCure provided conservative Q4 guidance of $139 million and anticipates 2026 revenues around $600 million, aligning with a long-term 13% growth CAGR. The company reported a strong Q3 gross margin of 75.5% and is well ahead of its 2028 adjusted EBITDA goal of 14%, demonstrating significant operating leverage.
- Management emphasizes that its markets are "completely underpenetrated" with "decades of growth ahead," focusing on execution rather than M&A as a priority. The Converge product, while not a near-term growth driver, is viewed as a long-term opportunity due to its clinical durability.
Nov 12, 2025, 1:40 PM
AtriCure Discusses Strong Q3 Performance, 2025 Guidance, and Future Growth Drivers
ATRC
Guidance Update
Product Launch
New Projects/Investments
- AtriCure reported a strong third quarter with sales upside and raised guidance for 2025.
- Growth is being driven by new product launches such as Flex Mini (appendage management), CryoSphere Max (pain management), and continued uptake of Encompass (open ablation).
- Significant clinical trials, Box X No AF and LEAPS, are expected to expand market opportunities, with data anticipated around 2028.
- The company is performing ahead of its long-range plan, targeting to be well ahead of its 20% adjusted EBITDA margin by 2030 goal.
- Despite competition, AtriCure maintains a 90-95% market share in the U.S. appendage management market, viewing competition as market validation.
Nov 10, 2025, 7:00 PM
AtriCure Reports Strong Q3 2025 Results and Raises Full-Year Guidance
ATRC
Earnings
Guidance Update
Product Launch
- AtriCure reported Q3 2025 worldwide revenue of $134.3 million, an increase of 15.8% year-over-year on a reporting basis, and achieved $17.8 million in adjusted EBITDA with an adjusted loss per share of $0.01.
- The company generated $30.1 million in cash during the quarter, ending with $147.9 million in cash and investments.
- AtriCure raised its full-year 2025 guidance, now projecting revenue between $532 million and $534 million and adjusted EBITDA between $55 million and $57 million.
- Growth was driven by strong adoption of new products, including the AtriClip FLEX Mini, CryoSPHERE MAX, and Encompass clamp, and progress in clinical trials such as LEAPS and the initiation of BoxX no-AF.
Oct 29, 2025, 8:30 PM
AtriCure Reports Third Quarter 2025 Financial Results and Raises 2025 Outlook
ATRC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- AtriCure reported worldwide revenue of $134.3 million for the third quarter of 2025, an increase of 15.8% year over year.
- The company's net loss for Q3 2025 was $0.3 million, an improvement of $7.6 million year over year, and Adjusted EBITDA increased by $9.9 million to $17.8 million.
- AtriCure generated $30.1 million of cash in the third quarter of 2025.
- Management raised its financial outlook for full year 2025, now projecting revenue between $532 million and $534 million and Adjusted EBITDA between $55 million and $57 million.
Oct 29, 2025, 8:01 PM
AtriCure Reports Q3 2025 Financial Results and Raises 2025 Outlook
ATRC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- AtriCure, Inc. reported worldwide revenue of $134.3 million for the third quarter of 2025, marking a 15.8% increase year over year.
- The company achieved a net loss of $0.3 million in Q3 2025, an improvement of $7.6 million compared to the third quarter of 2024.
- Adjusted EBITDA for Q3 2025 was $17.8 million, an increase of $9.9 million year over year.
- AtriCure generated $30.1 million in cash during the third quarter of 2025.
- The company raised its full year 2025 revenue outlook to approximately $532 million to $534 million and its Adjusted EBITDA outlook to approximately $55 million to $57 million.
Oct 29, 2025, 8:00 PM
AtriCure Initiates BoxX-NoAF Clinical Trial
ATRC
New Projects/Investments
Product Launch
- AtriCure, Inc. announced the treatment of the first patient in its BoxX-NoAF clinical trial on October 28, 2025.
- This prospective, multicenter, randomized, FDA-approved investigational device exemption (IDE) clinical trial will enroll up to 960 subjects at up to 75 sites worldwide.
- The trial aims to evaluate the safety and effectiveness of AtriCure's Isolator® Synergy™ EnCompass® clamp and AtriClip® Left Atrial Appendage Exclusion System in reducing new-onset atrial fibrillation (Afib) in cardiac surgery patients.
- If successful, the BoxX-NoAF trial could lead to expanded FDA labeling for these devices, positioning them as the only FDA-approved devices for the prevention of post-operative and longer-term clinical Afib.
Oct 28, 2025, 12:00 PM
AtriCure Discusses Strong Q2 2025 Growth and Long-Term Market Expansion
ATRC
Guidance Update
Product Launch
New Projects/Investments
- AtriCure reported accelerated growth in Q2 2025, reaching 17.1%, up from 13.6% in Q1, driven by new product launches like Cryosphere Max and AtriClip Flex Mini, leading to a raised guidance for the year.
- The company is pursuing a long-range plan to achieve $1 billion in revenue and 20%+ EBITDA margin by 2030, supported by an expanding market opportunity projected to grow from $5 billion+ to $10 billion by 2030.
- Key growth drivers include continued adoption of the Encompass clamp and strong performance of new products like Flex Mini, which saw 30% revenue growth in open appendage management in Q2.
- Significant market expansion is anticipated from clinical trials such as LEAPS and BOX-NOAF, which aim to triple the addressable market in cardiac surgery by treating non-AFib patients for stroke reduction and post-operative AFib prevention.
- While the hybrid business is currently under pressure from PFA technology, management expects a long-term rebound as PFA failure rates create a funnel for AtriCure's solutions, and the company is investing in its own PFA development program with first-in-human trials expected in late 2025 or 2026.
Sep 3, 2025, 8:52 PM
Quarterly earnings call transcripts for AtriCure.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more